MacroGenics Inc ((MGNX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MacroGenics Inc. is conducting a clinical study titled A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and preliminary antitumor activity of vobramitamab duocarmazine and lorigerlimab in patients with advanced solid tumors, including prostate cancer, melanoma, and others.
The study tests two biological interventions: vobramitamab duocarmazine, an antibody drug conjugate targeting B7-H3, and lorigerlimab, a bispecific DART® molecule that binds PD-1 and CTLA-4. These are administered intravenously every four weeks.
This non-randomized, sequential study is primarily focused on treatment. It involves multiple cohorts with different dose levels, aiming to determine the maximum tolerated dose.
The study began on April 19, 2022, with a primary completion date yet to be announced. The last update was submitted on July 25, 2025, indicating ongoing progress.
This update could influence MacroGenics’ stock performance positively if results show promising antitumor activity, potentially boosting investor confidence. The study’s progress is crucial in the competitive oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.